Navigation Links
Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study
Date:3/7/2012

cially available.

Information about Novartis clinical trials for pasireotide can be obtained by healthcare professionals at www.pasporttrials.com.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "can," "potential," "commitment," "look forward to," "expected," "will," or similar expressions, or by express or implied discussions regarding potential marketing approvals for pasireotide or regarding potential future revenues from pasireotide. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with pasireotide to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that pasireotide will be approved for sale in any market, or at any particular time. Nor can there be any guarantee that pasireotide will achieve any particular levels of revenue in the future. In particular, management's expectations regarding pasireotide could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Research and ... the addition of the "Micro Market Monitor: ... to their offering. ... treatment is progressing steadily, which has resulted in ... devices market. The main purpose of these dermatology ...
(Date:12/19/2014)... 2014  Decision Resources Group finds that the laparoscopic ... will increase to a value of over $4.3 ... expansion in the large direct energy device market. In ... adopted due to the advantages they offer and as ... from Decision Resources Group,s coverage of the U.S. laparoscopic ...
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3ResMed To Announce Second Quarter 2015 Results 2
... MOUNT PROSPECT, Ill., March 22, 2011 The National Association ... the prescription monitoring programs (PMPs) of North Dakota , ... agreements to participate in the PMP Interconnect ™ system, ... United States to be linked, providing a more effective means ...
... 22, 2011 The U.S. Food and Drug Administration ... Ann Arbor, Mich., and two of its officers, Mark ... Lincoln, vice president of Quality Assurance and Operations, have ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) The ...
Cached Medicine Technology:Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System 2Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System 3FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 2FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 3
(Date:12/21/2014)... Theme and plugin developers ... plugin for Final Cut Pro X entitled ProMotion. , ... more with absolute ease.” Said Christiana Austin, CEO of ... needed to easily animate their media inside FCPX.” , ... users to animate pictures, videos, logos, and more with ...
(Date:12/21/2014)... Downey, CA (PRWEB) December 21, 2014 The ... toy drive in the Santa Ana and Whittier offices. The ... help brighten the lives of patients and their families during ... to reach out to approximately 70 children between both offices. ... With the help of Target’s community service team, store managers ...
(Date:12/20/2014)... December 21, 2014 BambooIndustry.com is ... Recently, the business has announced its bamboo flooring ... the best material from certified suppliers, and offers ... customers worldwide. In the current promotion, all customers ... off, when they say they know BambooIndustry.com from ...
(Date:12/20/2014)... 20, 2014 An improving macroeconomic landscape ... benefited the Massage Services industry over the ... industry products, the anticipated 1.0% annualized increase in per ... consumers with the means to afford additional massages. “While ... massage in a given year has declined from 2009 ...
(Date:12/20/2014)... The print component of Healthy Aging is distributed within ... copies and an estimated readership of 420,000. The digital ... strategy and across a network of top news sites ... the campaign, click here . , The publication ... CTV’s The Social. Lainey Lui, Melissa Grelo, Traci ...
Breaking Medicine News(10 mins):Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2
... About ten years ago, the discovery of microRNAs ― ... unlocked a world of scientific possibilities, including a deeper ... "deep sequencing," which gives scientists the ability to discover ... Now, Tel Aviv University researchers have developed the cutting-edge ...
... departments when they,ve broken a leg, been stabbed or ... the Stanford University School of Medicine finds that 90 ... The high prevalence was surprising, said M. Kit Delgado, ... at Stanford,s Center for Primary Care and Outcomes Research, ...
... in daycare puts children with a chronic lung condition ... infections, according to a study from Johns Hopkins Children,s ... . The researchers say their findings should ... of age, for signs of lung disease and to ...
... HealthDay Reporter , SATURDAY, Sept. 25 (HealthDay News) ... as much water as they should, and the deficiency ... "Even mild dehydration can affect physiological function, and cause ... Heller, clinical nutrition coordinator at the Center for Cancer ...
... Lillian Feldshuh, of Scarsdale, NY, an early recipient of ... Patient Award yesterday at the Transcatheter Cardiovascular Therapeutics (TCT ... a success and Feldshuh, who will turn 100 years ... In 2006, Lillian Feldshuh suffered from aortic stenosis, a ...
... of the major disease states in the developed world. But ... You may experience stress as something that affects your entire ... if we zoom in on the building bricks of the ... differently. Stress can arise at the cellular level after exposure ...
Cached Medicine News:Health News:Diving deeper into the gene pool 2Health News:Preventive care poses dilemma for emergency departments, Stanford study finds 2Health News:Preventive care poses dilemma for emergency departments, Stanford study finds 3Health News:Daycare puts children with lung disease at risk for serious illness 2Health News:U.S. Kids Drink Too Little Water: Study 2Health News:U.S. Kids Drink Too Little Water: Study 3Health News:Stress can control our genes 2
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
... innovative E.coli 0157 latex ... definitive identification of E.coli ... of a proprietary antibody ... of cross-reactions with Escherichia ...
Inquire...
The Onar®Lp test system is an in vitro test for the qualitative diagnosis of legionella in clinical samples....
Medicine Products: